Nonstructural 5A protein (NS5A) of hepatitis C virus (HCV) is localized in the cytoplasm although it has a functional nuclear localization signal. To clarify the determinant of NS5A cytoplasmic localization, various N-or C-terminal deleted NS5A mutants were generated and their subcellular localization was analyzed in cell lines after transient expression. N-terminal deleted forms of NS5A were localized in the nucleus, and the sequence of the N-terminal 27 amino acids of NS5A had sufficient function to cause retention of a normally nuclear protein in the cytoplasm. These observations indicated that cytoplasmic localization of NS5A is determined primarily by the N-terminal region of the molecule. In addition, we found proteolytic processing of NS5A in transiently expressing cells. In these cells, cleavage occurred at a few sites located in the N-and C-terminal regions of NS5A. This cleavage in cells was enhanced by apoptotic stimuli and was inhibited by the caspase inhibitor Z-VAD-FMK, suggesting that a caspase-like protease(s) contributes to the cleavages of NS5A. Based on the results of mutational analysis of NS5A, we predicted one cleaved form, which had lost both the N-and the C-terminal portions of NS5A, to be composed of amino acid residues 155 to 389. Peptide containing the same amino acid sequence as this cleaved product was localized in the nucleus. Furthermore, we found that a fusion protein consisting of Gal4 DNA-binding domain fused with this cleaved form showed transcriptional activity only when the ␣-catalytic subunit of protein kinase A (PKA) was coproduced, suggesting that the transcriptional activity of this product was regulated by PKA. These results suggested that the cleavage product of NS5A by a caspase-like protease(s) plays a role in transcriptional regulation of the host cell gene(s) in HCV-infected cells.
INTRODUCTION
Hepatitis C virus (HCV) is a major causative agent of posttransfusion non-A, non-B hepatitis. HCV is a positive-sense, single-stranded RNA virus belonging to the third genus of Flaviviridae (Choo et al., 1991; Kato et al., 1990; Takamizawa et al., 1991) . The HCV genome has a single open reading frame that encodes a precursor polyprotein, and individual virus proteins are produced from the polyprotein by host and viral protease-mediated cleavage (Eckart et al., 1993; Grakoui et al., 1993a,b; Hijikata et al., 1991 Hijikata et al., , 1993a Hijikata et al., , 1993b Tanji et al., 1994a,b; Tomei et al., 1993) . The viral nonstructural 5A (NS5A) protein containing 447 amino acid (aa) residues is phosphorylated mainly at serine residues located in the Cterminal and central regions of the molecule (Asabe et al., 1997; Kaneko et al., 1994; Hirota et al., 1999; Tanji et al., 1995a,b) . Analysis of interferon (IFN)-treated HCVinfected patients for the viral genome revealed that amino acid mutations in the central or the C-terminal region of NS5A were correlated with increased sensitivity to IFN and low viral load (Duverlie et al., 1998; Enomoto et al., 1995 Enomoto et al., , 1996 Sato and Enomoto, 1998) . Recently, Gale et al. (1997 Gale et al. ( , 1998a Gale et al. ( , 1998b Gale et al. ( , 1999 reported that activity of IFN-induced double-stranded RNA-activated protein kinase (PKR), one of the antiviral proteins encoded by host cells, was repressed by NS5A through association with an IFN sensitivity-determining region (ISDR) located at the center of the NS5A molecule. The N-terminal deleted forms of NS5A fused to the DNAbinding domain of Gal4 activated transcription of a reporter gene driven by Gal4 in yeast and human hepatoma cells, suggesting that NS5A has a potent transcriptional activity (Kato et al., 1997; Tanimoto et al., 1997) . Furthermore, mutations in the ISDR have been shown to affect the transcriptional activity of NS5A (Fukuma et al., 1998) .
A previous study showed that NS5A has a functional nuclear localization signal (NLS) sequence (PPRKKRTVV, aa residues 354-362) that is competent to target a protein, Escherichia coli ␤-galactosidase, to the nucleus when fused to its N-terminus (Ide et al., 1996) . However, the intact form of NS5A protein is localized mainly in the cytoplasm of hepatocytes in chronically HCV-infected patients or NS5A-expressing mammalian cells. Thus, it remains to be clarified whether NS5A is transported from the cytoplasm to the nucleus during the HCV replication cycle, and the roles, if any, of this trafficking event in HCV pathogenesis remain to be determined.
In this study, we demonstrated that the N-terminal deleted forms of NS5A were localized in the nucleus and the peptide with the N-terminal 27 aa residues was sufficient to retain a nuclear protein in the cytoplasm when fused to its N-terminus. These observations indicated that the cytoplasmic localization of NS5A was conferred by the N-terminal region of this molecule. Furthermore, we found that cleavage of NS5A occurred in NS5A-expressing cells, and the cleavage of NS5A was enhanced by apoptotic stimuli. A peptide containing the same amino acid sequence as one of the cleaved forms of NS5A was localized in the nucleus and had potent transactivating function in transiently expressing cells. These observations highlight the function of nuclear localization of NS5A in the HCV replication cycle.
RESULTS

Subcellular localization of various NS5A mutants in mammalian cells
We and others have shown previously that NS5A is localized in the cytoplasm even though it has a functional NLS (Fipaldini et al., 1999; Ide et al., 1996; Tanji et al., 1995b) . To clarify the determinant of NS5A cytoplasmic localization, we analyzed the subcellular localization of various N-or C-terminal deleted NS5A mutants. We constructed each NS5A mutant fused with the E-tag epitope at its C-terminus. These epitope-tagged NS5A mutants were expressed in Saos-2 cells, and we examined the subcellular localization of these proteins by indirect immunofluorescence staining with anti-E-tag antibody 24 h after transfection. Full-length NS5A, 5A1-447, and the C-terminal deleted form of NS5A, 5A1-378E, were localized in the cytoplasm, whereas the N-terminal deleted form and both N-and C-terminal deleted form of NS5A, 5A163-447E, or 5A163-378E, respectively, were predominantly localized in the nucleus (Fig. 1A) . In other experiments, we found that deleting only 27 aa residues of the N-terminus was sufficient to translocate NS5A to the nucleus (data not shown). The subcellular localization of each NS5A mutant is shown in Fig. 1B . These observations indicated that deleting the N-terminus of NS5A caused localization of the protein to the nucleus. Among these deleted NS5A mutants, 5A163-378E, lacking both Immunofluorescence staining of Saos-2 cells expressing NS5A mutants fused with the E-tag epitope at their C-termini; i.e., full-length (5A1-447E), C-terminally deleted form (5A1-378E), N-terminally deleted form (5A163-447E), and N-and C-terminally deleted form (5A163-378E). Saos-2 cells transfected with expression plasmids for NS5A derivatives were fixed and stained with anti-E-tag antibody, and the immunecomplexes were detected with rhodamine-conjugated secondary antibodies (top). Staining of the nucleus by DAPI in the same cells is also shown (bottom). (B) Schematic representation of NS5A and its derivatives and their subcellular localization. Subcellular localization of various NS5A derivatives is shown on the right side of the figure as follows: C, predominantly cytoplasmic localization; N, predominantly nuclear localization. Numbers above the illustration show aa position from the N-terminus of NS5A. Localization of NLS in NS5A from aa 354 to 362 is shown by the solid bar. The names of the NS5A derivatives are shown on the left.
terminal sequences of NS5A but containing the NLS region, was localized to the nucleus, while another form, 5A163-278E, which had a larger C-terminal deletion than 5A163-378E and lacked the NLS region, was predominantly found in the cytoplasm, suggesting that a previously identified NLS between 278 and 378 aa residues of NS5A functions as a nuclear targeting signal of the N-terminal deleted NS5A.
The N-terminal 27 aa residues of NS5A are sufficient to retain a nuclear protein in the cytoplasm
The observation that the N-terminal deleted form of NS5A was localized to the nucleus could be interpreted in one of two ways: (1) the NLS sequence of NS5A may be masked conformationally by its N-terminal sequence, and thereby the recognition of the NLS sequence with a nuclear importing factor such as importin could be inhibited, or (2) the N-terminal sequence of NS5A may be a cytoplasm retention signal (CRS) that is competent to target a protein to the cytoplasm and is more effective than the NLS sequence of NS5A. To verify which of these possibilities is correct, we constructed an expression plasmid from which a fusion protein with the sequence of the N-terminal 27 aa residues of NS5A to the N-terminus of HCV core mutant, ⌬core151, was produced ( Fig. 2A) . It has been reported that the intact core protein is localized to the cytoplasm, while ⌬core151, with deletion of the C-terminal 40 aa residues, was localized to the nucleus (Liu et al., 1997; Marusawa et al., 1999; Suzuki et al., 1995) . The plasmid encoding this fusion protein, designated 5A1-27⌬core151, was transfected into Saos-2 cells, and the subcellular localization of this protein was examined by immunofluorescence using anti-core antibody. Figure 2B shows that this fusion protein was localized to the cytoplasm (middle), whereas ⌬core151 itself was predominantly localized to the nucleus as expected (left). This alteration of subcellular localization by fusion of the N-terminal 27 aa residues of NS5A was specific since fusion of the other NS5A-derived sequence, spanning residues 28 to 77, to the N-terminus of ⌬core151 showed no effect on subcellular localization (Fig. 2B,  right) . These results indicated that NS5A has a CRS region within its N-terminal 27 aa residues.
NS5A is cleaved by a caspase-like protease(s) in cells
Our results indicated that NS5A can translocate to the nucleus if its N-terminus is removed. Thus, we examined whether N-terminally deleted forms of NS5A could be produced by proteolytic processing in NS5A-expressing cells. When NS5A was transiently produced in Saos-2 cells, proteins that migrated faster than the authentic 56-kDa NS5A protein were detected by the anti-NS5A antibody (Fig. 3, lane 2) . Furthermore, we observed that, despite a decrease in the 56-kDa NS5A protein level, two bands of 48 and 31 kDa were both enhanced in a timedependent manner after exposure to apoptotic stimuli such as tumor necrosis factor-␣ (TNF-␣) plus cycloheximide (CHX) or poly(I-C) plus CHX (Fig. 3 , lanes 2 to 6; and data not shown). In addition, we observed that processing of the authentic NS5A protein was suppressed by pretreatment with the caspase inhibitor carbobenzoxy-L-valyl-L-alanyl-L-b-methyl-aspart-1-yl-fluoromethane (Z-VAD-FMK) before the addition of an apoptotic stimulus (Fig. 3, lane 7) . These phenomena were also observed in HeLa and HepG2 cells (data not shown). These observations suggested that the NS5A protein was cleaved in the cells by a caspase-like protease(s) and the resulting processed products accumulated in the cells. We tried to confirm the processing of NS5A in cells expressing the entire HCV polyprotein. However, production of NS5A from the entire HCV polyprotein was too low for its processing to be analyzed. Thus, it is necessary to develop an efficient protein expression system to analyze NS5A processing.
FIG. 2.
The sequence of the N-terminal 27 aa residues of NS5A functions as a cytoplasm retention signal. (A) Saos-2 cells were transfected with plasmids expressing three types of ⌬core151 derivative; i.e., ⌬core151 itself, ⌬core151 fused at its N-terminus with the sequence from aa 1 to 27 of NS5A (5A1-27⌬core151), and ⌬core151 fused at its N-terminus with the sequence from aa 28 to 77 of NS5A (5A28-77⌬core151). The lysates of Saos-2 cells were fractionated by SDS-15% PAGE followed by blotting analysis using the anti-core antibody. (B) Immunofluorescence staining of Saos-2 cells expressing ⌬core151 fusion proteins. Saos-2 cells transfected with plasmids expressing proteins denoted above each panel were fixed and stained with anticore antibody, and the immunecomplexes were detected with rhodamine-conjugated secondary antibodies (top). The staining of the nucleus by DAPI in the same cells is also shown (bottom).
Presence of multiple cleavage sites for caspase-like protease(s) in NS5A
The anti-NS5A antibody used in this study recognizes the region from aa residues 228 to 278 in NS5A (Fig. 4A) . To determine the cleavage site(s), we expressed NS5A tagged at its N-or C-terminus with a marker peptide in Saos-2 cells. Then, the cells were treated with CHX in the presence or in the absence of TNF-␣ for 8 h. Cell lysate was prepared and analyzed for NS5A protein using the anti-NS5A antibody or antibodies against each tag. When NS5A protein tagged with green fluorescent protein (GFP) at its C-terminus, 5A-GFP (83 kDa), was produced in Saos-2 cells, an 83-kDa protein of the expected size from the amino acid composition of the fusion protein was produced. Cleaved forms of 48 and 31 kDa were detected by the anti-NS5A antibody, and production of the cleaved forms was enhanced by treatment with TNF-␣ (Fig. 4B , top, lanes 5 and 6). Importantly, cleaved products with the same molecular masses were also detected when authentic NS5A was produced in Saos-2 cells (Fig. 4B , top, lanes 3 and 4). Thus, it was suggested that these two cleaved products were produced by cleavage at least in the C-terminal region of NS5A. Furthermore, in 5A-GFP-expressing cells, a 35-kDa protein (about 8 kDa larger than the parent GFP) was detected by anti-GFP antibody (Fig. 4B , bottom, lanes 5 and 6), suggesting that the C-terminal cleavage site is located close to 70 aa residues from the C-terminus of NS5A.
When NS5A protein tagged with FLAG at its N-terminus, FLAG-5A, was produced in Saos-2 cells, 50-and 31-kDa cleaved forms of FLAG-5A in addition to the product of the expected size (58 kDa) were mainly detected by the anti-NS5A antibody (Fig. 4B , top, lane 7 and 8). The 50-kDa protein was about 2 kDa larger than the cleaved product of 48 kDa, which was observed in cells expressing authentic NS5A. This 50-kDa protein was detected by anti-FLAG antibody (Fig. 4B , bottom, lanes 7 and 8), indicating that its N-terminus reflects that of FLAG-5A. As a 31-kDa protein of the FLAG-5A derivative was recognized by the anti-NS5A antibody but not by the anti-FLAG antibody (Fig. 4B , top and bottom, lanes 7 and 8), it was estimated to be the N-terminally cleaved form of FLAG-5A. Furthermore, in FLAG-5A-expressing cells, a 19-kDa cleaved form was detected by anti-FLAG antibody (Fig. 4B , bottom, lanes 7 and 8), suggesting that it was produced by cleavage close to 150 aa residues from the N-terminus of authentic NS5A. In addition, we observed the production of a 32-kDa cleaved form of FLAG-5A, which was recognized by anti-FLAG antibody but not by the anti-NS5A antibody (Fig. 4B , top and bottom, lanes 7 and 8), indicating that an additional cleavage site in FLAG-5A was located 270 aa residues from the N-terminus of the authentic NS5A. Failure to detect the C-terminal half of FLAG-5A produced by cleavage close to 270 aa by the anti-NS5A antibody might have been due to destruction of the epitope for the anti-NS5A antibody used in this study, because the epitope for this antibody was estimated to be localized in the region surrounding the cleavage site. A 31-kDa protein was detected by the anti-NS5A antibody in cells expressing authentic NS5A as well as the N-or Cterminally tagged NS5A derivative but was not detected by the antibodies for each tag, suggesting that the 31-kDa protein was an N-and C-terminally cleaved form of NS5A.
These observations suggested that NS5A is cleaved at at least three sites. As cleavage at these sites was not efficient, several cleaved products were expected to be produced. One cleavage site may be located in the possible epitope region for the anti-NS5A antibody. Thus, peptides having this cleaved site at the N-or C-terminus may not be recognized by the antibody. Peptides that do not have the epitope sequence also are not recognized by the antibody. Thus, only a few cleaved products of NS5A could be detected by the anti-NS5A antibody.
We detected a 41-kDa fragment in NS5A-and 5A-GFPexpressing cells and a larger form of 2 kDa in FLAG-5A-expressing cells by the anti-NS5A antibody (Fig. 3 , lane 2, and Fig. 4B , top, lanes 3, 5, and 7). Furthermore, a faint band of a 43-kDa fragment in FLAG-5A-expressing cells was detected by anti-FLAG antibody when the film for Western blotting was exposed for a long period (data not shown). These data indicated that the 41-kDa fragment detected by the anti-NS5A antibody in NS5A-expressing cells contained the N-terminal portion of NS5A. However, it is not yet clear how this molecule is produced in NS5A-expressing cells. We also observed that the level of this fragment was decreased with time after apoptotic   FIG. 3 . Cleavage of NS5A in Saos-2 cells by caspase-like protease(s). Saos-2 cells transfected with a control expression plasmid pKS(ϩ)/CMV (lane 1) or NS5A expression plasmid pCMV/5A1-447 (lanes 2 to 7) were pretreated with (lane 7) or without (lanes 1 to 6) 50 M Z-VAD-FMK for 1 h and then treated with 10 ng/ml TNF-␣ plus 50 g/ml CHX for the times indicated above panel. The cell lysates were fractionated by SDS-10% PAGE followed by Western blotting using the anti-NS5A antibody. NS5A (56 kDa) and apoptosis-enhanced cleavage products of NS5A, 48-and 31-kDa products, are shown on the right with arrows. The positions of molecular mass markers (in kilodaltons) are shown on the left. stimulus (Fig. 3 , lanes 2 to 6), suggesting that it was proteolytically processed during apoptosis.
Mapping of the caspase cleavage sites in NS5A
The above results suggested that there are at least three caspase-mediated cleavage sites in NS5A. To determine these cleavage sites, we examined production of cleavage products from mutagenized NS5A derivatives at the likely sites for caspase recognition. Since the above observations suggested that one cleavage site was located close to 150 aa residues from the N-terminus, we surveyed the amino acid sequence surrounding this position of NS5A for an appropriate caspase cleavage motif. We found an Asp residue at position 154 as a potential cleavage site for caspases (Thr-Glu-Leu-Asp 154 / Gly). To verify that this position was indeed one of the cleavage sites in NS5A, we constructed a plasmid to produce the mutant form of FLAG-5A by replacing Asp at this position with Glu and designated this protein FLAG-5AD154E. When FLAG-5AD154E was produced transiently in Saos-2 cells, the 31-kDa cleaved form, as seen in Saos-2 cells producing FLAG-5A, was not detected by the anti-NS5A antibody even after apoptotic stimulation (Fig. 5, top, lanes 5 and 6) . Furthermore, the 19-kDa cleaved form of FLAG-5A was not detected by anti-FLAG antibody, while the 50-and 32-kDa cleaved forms were detected (Fig. 5, bottom, lanes 5 and 6) . These observations indicated that the position at Asp 154 /Gly in NS5A is one of the cleavage sites targeted by the caspase-like protease(s) and Gly 155 is likely to be the N-terminus of the 31-kDa protein recognized by the anti-NS5A antibody. In comparison with FLAG-5A-producing cells, the 50-kDa cleaved product recognized by both anti-NS5A and anti-FLAG antibodies accumulated to higher levels in FLAG-5AD154E-producing cells, suggesting that this 50-kDa protein was the intermediate in production of the 31-kDa protein.
Based on the results shown in Fig. 4B , the C-terminal cleavage site was estimated to be located close to 70 aa residues from the C-terminus of NS5A. We found an Asp   FIG. 4 . Cleavage of N-or C-terminally tagged form of NS5A by caspase-like protease(s). (A) Schematic representations of NS5A, NS5A tagged at the C-terminus with green fluorescent protein (5A-GFP), and NS5A tagged at the N-terminus with FLAG peptide (FLAG-5A). The top bar above the representation for 5A indicates the region of the epitope for the anti-NS5A antibody, and numbers 228 and 278 show the N-and C-terminal aa residues of the epitope. (B) Saos-2 cells transfected with a control expression plasmid pKS(ϩ)/CMV (vect.) or NS5A derivative expression plasmids, as denoted above panel, were treated with 50 g/ml CHX in the presence (ϩ) or in the absence (Ϫ) of 10 ng/ml TNF-␣ for 8 h. The cell lysates were fractionated by SDS-PAGE followed by blotting using the anti-NS5A antibody (top), anti-GFP antibody (bottom, left), or anti-FLAG antibody (bottom, right). The positions of NS5A, 5A-GFP, FLAG-5A, and apoptosis-enhanced cleavage products are shown on the right with arrows. The molecular mass markers (in kilodaltons) are shown on the left of each panel.
residue at position 389 as a potential cleavage site for caspases (Ser-Ala-Val-Asp 389 /Ser). When the mutant form of FLAG-5A, FLAG-5AD389E, in which Glu at position 389 was substituted for Asp, was produced in Saos-2 cells with or without TNF-␣ treatment, a 39-kDa cleaved form was detected by the anti-NS5A antibody, but 50-and 31-kDa cleaved forms, as seen in FLAG-5A, were not detected by the anti-NS5A antibody (Fig. 5, top, lanes 7  and 8) . In this mutant, however, generation of the 19-and 32-kDa cleaved forms detected by anti-FLAG antibody was not affected (Fig. 5, bottom, lanes 7 and 8) . These observations showed that the C-terminal cleavage site in NS5A is located at position Asp 389 /Ser, and Asp 389 is likely to be the C-terminus of the 50-and 31-kDa cleaved forms of FLAG-5A. Thus, the 31-kDa cleaved form of NS5A was likely to encode the residues from aa 155 to 389, containing the NLS region. When a protein of 5A155-389 corresponding to the 31-kDa cleaved form of NS5A was produced in Saos-2 cells, it was shown to be localized in the nucleus as expected (data not shown).
We found that in the series of FLAG-5A-expressing cells treated with TNF-␣, a slower migrating band of the 32-kDa fragment derived from FLAG-5A and FLAG-5AD389E, but not from FLAG-5AD154E, was detected by anti-FLAG antibody (Fig. 5, bottom, lanes 4, 6, and 8) . It is possible that mobility of the 32-kDa protein may be affected by modification such as phosphorylation after TNF-␣ treatment. However, such a modification might not affect the change in mobility of the mutated form of the 32-kDa protein derived from FLAG-5AD154E.
The 31-kDa cleaved product of NS5A showed enhanced transcriptional activation when the ␣-catalytic subunit of PKA was coproduced Previously, it was reported that the fusion protein consisting of Gal4 DNA-binding domain (Gal4-dbd) and the N-terminal deleted NS5A showed a transcriptional activation effect in hepatoma cells on the reporter gene that contains Gal4 DNA sequences in the promoter (Kato et al., 1997) . We examined whether the 31-kDa cleaved product of NS5A encoding residues from aa 155 to 389 had such an activity in HepG2 cells. Gal4-5A155-389, consisting of Gal4-dbd and the residues from aa 155 to FIG. 5 . Mapping the cleavage sites in NS5A. Saos-2 cells transfected with a control expression plasmid pKS(ϩ)/CMV (vect.) or FLAG-5A mutant expression plasmids, as denoted above panel, were treated as described in the legend to Fig. 4B . The cell lysates were fractionated by SDS-10% PAGE (top) or SDS-15% PAGE (bottom), followed by blotting using anti-NS5A antibody or anti-FLAG antibody, respectively. The positions of 58-kDa full-length FLAG-5A mutants and apoptosis-enhanced cleavage products are shown on the right with arrows. Open circles in panels indicate apoptosis-enhanced cleavage products. The molecular mass markers (in kilodaltons) are shown on the left. 389 of NS5A derived from the HCV clone used throughout this experiment, was localized in the nucleus (data not shown) and showed a weak transcriptional activation effect (Fig. 6A, top) . Such weak activity was also observed when the NS5A sequence from another clone of HCV (designated NS5A-NK) derived from the serum of a 53-year-old female patient with HCV type 1b chronic active hepatitis (Kato et al., 1997) was used (Fig. 6A,  bottom) . The transcriptional activity of Gal4-5A155-389 seemed to be saturated because changes in the expression level of this protein did not alter the activity (data not shown).
Since the activities of some transcription factors are regulated by phosphorylation and NS5A is phosphorylated in vitro by the ␣-catalytic subunit of PKA , we investigated whether transcriptional activation of NS5A was regulated by PKA. When Gal4-dbd-containing NS5A derivatives were coexpressed with the ␣-catalytic subunit of PKA in HepG2 cells, Gal4-5A155-389 showed strong transcriptional activation, although the full-length NS5A showed no activation (Fig. 6B) . These results suggested that the potential transcriptional activity governed by the portion from aa 155 to 389 of NS5A is suppressed under normal conditions but this suppression can be released by proteolytic cleavage followed by phosphorylation mediated by PKA. The different levels of transcriptional activity of Gal4-5A155-389 derived from different isolates of HCV seemed to reflect their characteristic features and were not dependent on expression level (data not shown).
DISCUSSION
We and others have shown that HCV NS5A protein is localized in the cytoplasm or perinucleoplasm but not in the nucleus although NS5A contains a functional NLS sequence (PPRRKRTVV) that is present in the region from aa 354 to 362, proximal to the C-terminus (Fipaldini et al., FIG. 6 . Analysis of transcriptional activity of NS5A and its derivatives. HepG2 cells were cotransfected with each Gal4-fusion protein expression plasmid (pM plasmids) and a reporter plasmid, pFR-Luc, with (B) or without (A) pFC-PKA, which expresses the ␣-catalytic subunit of PKA. Luciferase activities of cells producing NS5A or its derivatives are shown relative to control cells (pM-transfected cells). The structure of plasmids in this figure is described under Materials and Methods.
1999; Ide et al., 1996; Tanji et al., 1995b) . In this study, we found that N-terminally deleted forms of NS5A, with deletion of at least 27 aa residues, were localized predominantly in the nucleus, but deletion of the NLS region from this mutant resulted in localization in the cytoplasm. Furthermore, we clearly showed that the 27 aa of the N-terminus of NS5A functions as a CRS by demonstrating that a nuclear localizing protein, ⌬core151, was retained in the cytoplasm when fused with the N-terminal 27 aa residues of NS5A at the N-terminus of this protein.
These results suggested that the function of the N-terminus CRS is dominant over that of the NLS located in the C-terminal region, and thereby full-length NS5A is localized in the cytoplasm. However, it is not known how CRS determines the subcellular localization of NS5A. Recently, Tu et al. (1999) reported that NS5A directly interacted with human vesicle-associated membrane protein-associated protein of 33 kDa (hVAP-33). It is interesting to examine whether the N-terminal CRS region of NS5A interacts with hVAP-33 and this interaction contributes to cytoplasmic, in particular, perinucleoplasmic localization of NS5A. To clarify the mechanism of cytoplasmic retention of NS5A, the physiochemical properties of the CRS sequence as well as screening for molecules that interact with CRS in cells may be required.
We showed that NS5A was cleaved by a caspase-like protease(s) at a few sites in cells and at least two cleaved forms of NS5A, one with a C-terminal deletion and the other with both N-and C-terminal deletions, were detected by the anti-NS5A antibody that recognizes an epitope spanning aa 228 to 278. A 41-kDa fragment containing the N-terminal portion of NS5A was also detected by the anti-NS5A antibody in NS5A-expressing cells, suggesting that a cleavage site is located close to aa residue 350. No appropriate caspase recognition sites were seen around this position, and thus this fragment was proteolytically produced independent of caspase.
Based on the results of the mutagenesis study, we defined two possible cleavage sites mapped between Asp 154 and Gly 155 and between Asp 389 and Ser 390 . We did not define the third cleavage site localized in the region from aa 228 to 278. For two cleaved proteins detected by the anti-NS5A antibody, we speculated that the C-terminally deleted form encodes residues aa 1 to 389, and the N-and C-terminally deleted form encodes residues aa 155 to 389. The N-and C-terminally cleaved form, designated 5A155-389, carries the NLS. In fact, it was shown to be localized in the nucleus when transiently expressed in Saos-2 cells (data not shown). NS5A appeared to be cleaved by a caspase-like protease(s), and then some of the cleavage products were translocated to the nucleus. Since cleavage at each site seemed to be relatively inefficient, partially cleaved forms are expected to accumulate in NS5A-producing cells. However, the C-terminal fragment cleaved only at Asp 154 /Gly, with an expected size of 39 kDa, was rarely detected by the anti-NS5A antibody in NS5A-expressing cells, suggesting that cleavage at Asp 389 /Ser or at the site in the region of the epitope for the anti-NS5A antibody may be preferred by the caspase-like protease(s) rather than the site at Asp 154 /Gly. Since the 31-kDa protein contained the cleavage site at the region in the epitope, it is likely that cleavage at Asp 389 /Ser occurs with the highest priority. Recently, Lohman et al. (1999) reported a small amount of NS5A protein staining in the nucleus in a hepatoma cell line transfected with subgenomic HCV type 1b RNA. We attempted to detect nuclear localization of NS5A in NS5A-expressing Saos-2 or HepG2 cells with or without apoptotic stimulus. However, the amounts of NS5A localized to the nucleus were too low to be detected by immunofluorescence using our NS5A antibody in these cell lines.
As shown in Fig. 7 , the amino acid residue of Asp 154 is well conserved and residues around Asp 154 are highly conserved among HCV isolates. However, Asp 389 was conserved only in HCV type 1b. Thus, it appears that cleavage at Asp 154 /Gly is common to all HCV isolates, but that at Asp 389 /Ser occurs specifically in HCV type 1b. When Asp 389 of HCV-1b NS5A was replaced with Glu, cleavage did not occur at this site (Fig. 5, lanes 7 and 8) . However, the N-terminal deleted form was produced by cleavage at Asp 154 /Gly, suggesting that cleavage at Asp 389 /Ser is not essential for nuclear localization of NS5A. Thus, it is likely that nuclear localization of NS5A can be observed irrespective of HCV genotype upon cleavage at Asp 154 . Although the function of NS5A has not been fully clarified, NS5A is known to be phosphorylated (Kaneko et al., 1994; Tanji et al., 1995b) , to suppress interferoninduced double-stranded RNA-dependent protein kinase (Gale et al., 1997 (Gale et al., , 1998a (Gale et al., , 1998b , and to regulate the antiviral activity of IFN (Polyak et al., 1999; Song et al., 1999) . It has also been shown that the C-terminal domain of NS5A contains a transcriptional transactivating function (Kato et al., 1997; Tanimoto et al., 1997) . These observations suggested that NS5A plays some role in viral replication through these functions. We confirmed the transcriptional activation by Gal4-5A163-359 of a reporter gene with the Gal4 DNA sequence in its promoter as reported by Kato et al. (1997) . However, we observed very weak transcriptional activation by Gal4-5A155-389, in which the entire amino acid sequence of the 31-kDa protein, the N-and C-terminal cleaved product of NS5A, was present (Fig. 6A) . Importantly, Gal4-5A155-389 showed significant transactivating function when expressed along with the ␣-catalytic subunit of PKA (Fig.  6B) , suggesting that the transcriptional activity of 5A155-389 was activated by PKA-mediated phosphorylation. In addition, we observed that the activity of 5A163-359, in which 8 and 30 aa were truncated from the N-and C-termini of 5A155-389, respectively, was also enhanced by the presence of PKA, indicating that there may be a mechanism for PKA-mediated enhancement of transcriptional activation by NS5A. It has been shown that NS5A was phosphorylated by the ␣-catalytic subunit of PKA in vitro . It is interesting to note that at least five consensus PKA phosphorylation sequence motifs, RXS/T* and RXXS/T* (where X is any amino acid residue and the asterisk denotes that the residue is phosphorylated), are present in the region spanning aa 155 to 389. To clarify the mechanism of PKA-mediated transcriptional activation, it is important to determine whether 5A155-389 is indeed phosphorylated by PKA in vivo, and, if any, the target amino acid for PKA phosphorylation in 5A155-389. Association of NS5A with DNA is not observed. Thus, it is unclear how NS5A cleavage products play a role in regulating transcriptional activity of cellular genes. It is possible that NS5A interacts with a cellular transcription factor, and this interaction may be involved in the regulation of gene expression.
We observed that the fusion protein consisting of Gal4-dbd and full-length NS5A was localized in the cytoplasm but not in the nucleus (data not shown), which may be one of the reasons that the full-length NS5A did not show transcriptional activation irrespective of expression of the ␣-catalytic subunit of PKA.
We examined the effect of NS4A, which is shown to be important for hyperphosphorylation of NS5A (Kaneko et al., 1994) , on the cleavage of NS5A and Gal4-5As-dependent transcriptional activity. However, coproduction of NS4A did not affect them even in the presence or in the absence of PKA (data not shown). We are currently investigating the effect of other HCV proteins.
In this study we showed that NS5A was cleaved by a caspase-like protease(s) and the peptide containing the same amino acid sequence as one of the cleaved products, 31-kDa protein, was localized in the nucleus. However, the physiological roles of the modification of NS5A such as cleavage and resultant changes in subcellular localization of NS5A in HCV replication as well as pathogenic roles in liver dysfunction remain to be clarified. Previously, it was shown that NS5A is anti-apoptotic . It is likely that the proteolytically produced 31-kDa fragment contributes to anti-apoptotic function of NS5A through trans-activation of an antiapoptotic gene, like hsp70 (Jäättelä et al., 1998) , which functions downstream of the caspase(s). To clarify the role of NS5A or the cleaved products, we are currently investigating its effect on apoptosis. Gale et al. (1999) also reported that suppression of PKR activity is required for the oncogenic properties of NS5A, but NS5A has growth-stimulatory potential that is independent of the ability to regulate PKR. Furthermore, Ghosh et al. (1999) reported that NS5A modulates cell cycle regulatory genes, such as p21 WAFI and the human proliferating cell nuclear antigen gene, and promotes cell growth. The 31-kDa fragment of NS5A, a potent transcriptional activator that is localized to the nucleus, was also detected in NS5A-expressing cells without apoptotic stimulus (Fig.  3, lane 2) , suggesting that the 31-kDa fragment of NS5A is produced irrespective of apoptotic induction and functions as a potent transactivator under physiological conditions of HCV infection. Thus, it may be interesting to investigate whether this fragment affects cell growth irrespective of apoptosis. Screening for cellular target genes of NS5A is necessary to clarify the roles of transcriptional activation of NS5A in the HCV replication cycle.
MATERIALS AND METHODS
Construction of plasmids
Construction of plasmids pCMV/5A1-447 (designated pCMV/N1973-2419 in Kaneko et al., 1994) , pCMV/5A1-447E (Hirota et al., 1999) , pCMV/5A1-378E (Hirota et al., 1999) , pCMV/5A163-447E (designated pCMV/N2135-2419E in Asabe et al., 1997) , and pCMV/5A28-447E (designated pCMV/N2000-2419E in Asabe et al., 1997) were reported previously. The plasmids pCMV/5A163-378E and pCMV/N163-278E were constructed by inserting the PstI-EcoRI fragment of PCR products amplified using pCMV/5A1-447 as a template with the sense primer, 5Ј-AAACTGCAGCCATGCCGGCGTGCAGACCT-3Ј, and antisense primer, 5Ј-CCGGAATTCCTTAGTAGCCAGCTC-CGC-3Ј, or 5Ј-CCGGAATTCCTCCTTATTCTCTGA-3Ј, respectively, into the PstI-EcoRI site of pCMV/C-E-tag (Asabe et al., 1997) . The plasmid pCMV/5A155-389E was constructed by inserting the PstI-EcoRI fragment of the PCR product amplified using pCMV/5A1-447 as a template with the sense primer, 5Ј-AAAACTGCAGCCAT-GGGGGTGCGGTTGCACAGG-3Ј, and antisense primer, 5Ј-CCGGAATTCGTCAACGGCCGACGATCC-3Ј, into the PstI-EcoRI site of pCMV/C-E-tag. The plasmid pCMV/ 5A1-149E was obtained by removing the EcoRI fragment of pCMV/5A1-447E followed by re-ligation. Construction of the plasmid pCMV/⌬core151 encoding a C-terminal 40 aa deleted HCV core protein was reported previously (Marusawa et al., 1999) . To obtain the plasmid pCMV/ 5A1-27⌬core151 or pCMV/5A28-77⌬core151, the PstIBamHI fragment of the PCR product amplified using pCMV/5A1-447 as a template with the primer combinations 5Ј-AAACTGCAGCCATGTCCGGCTCGTGGCTAAG-G-3Ј and 5Ј-CGCGGATCCGAGCTTGGACTGGAGCCA-3Ј or 5Ј-AAACTGCAGCCATGCTGCCGAAATTGCCG-3Ј and 5Ј-CGCGGATCCAGGCCCAACGATCCTCAT-3Ј, respectively, was inserted into the PstI-BamHI site of pCMV/ ⌬core151. The resultant plasmids, pCMV/5A1-27⌬-core151 and pCMV/5A28-77⌬core151, encoded ⌬core151 fused at its N-terminus with the NS5A-derived residues consisting of aa 1 to 27 or aa 28 to 77, respectively. The plasmid pCMV/5A-GFP, expressing NS5A protein tagged with GFP at its C-terminus, was constructed as follows. The GFP fragment obtained by digestion of pQBI25 (TaKaRa) with NheI and EcoRI was filled in with Klenow, and the resulting fragment was then ligated with the fragment of pCMV/5A1-447E prepared by digestion with ClaI and BamHI followed by filling in the ends with Klenow. The plasmid pCMV/FLAG-5A, expressing NS5A protein tagged with the FLAG epitope at its N-terminus, was constructed by inserting an annealed oligo DNA fragment (sense, 5Ј-TCGAAGAGCTCCACCATGGACTA-CAAGGACGACGATGACAAGC-3Ј, and 5Ј-TCGAGCTTGT-CATCGTCGTCCTTGTAGTCCATGGTGGAGCTCT-3Ј) into the XhoI site of pCMV/5A1-447. To obtain mutant forms of FLAG-5A replacing Asp with Glu at residue 154 or 389, designated FLAG-5AD154E or FLAG-5AD389E, respectively, two-step PCR using pCMV/5A1-447 as a template was performed. In the first-step PCR, products designated D154E-C and D389E-C were obtained with the following combinations of sense and antisense primers: D154E-C, 5Ј-ACTGAACTCGAGGGGGTGCGGTTGCAC-3Ј and 5Ј-TCACTGCATTCTAGTTGTGG-3Ј; D389E-C, 5Ј-TCG-GCCGTTGAGCTCGGCACGGCGACCGCC-3Ј and 5Ј-TCACTGCATTCTAGTTGTGG-3Ј. 5AD154E and 5AD389E were obtained by second-step PCR using combinations of the primer 5Ј-AAACTGCAGCCATGTCCGGCTCGTG-GCTAAGG-3Ј and D154E-C, and D389E-C, respectively. The resultant products, 5AD154E and 5AD389E, were digested with PstI and AccI and then exchanged with the PstI-AccI fragment of pCMV/FLAG-5A to obtain pCMV/ FLAG-5AD154E and pCMV/FLAG-5AD389E, respectively.
To generate a Gal4-dbd/NS5A fusion protein in cells, the PCR products amplified using pCMV/5A1-447 or pM-NS5A/F5-R5 (Kato et al., 1997 ) (a gift from N. Kato, consisting of full-length NS5A derived from the serum of a 53-year-old male patient with HCV type 1b chronic active hepatitis) as a template were inserted into the BamHIHindIII site of pM (Clontech), which expresses N-terminal Gal4-dbd fusion protein in mammalian cells. pM/5A1-447, pM/5A155-389, and pM/5A163-359 were obtained using pCMV/5A1-447 as a template with primers F1 and R1, F2 and R2, and F3 and R3, respectively. pM/5A155-389(NK) and pM/5A163-359(NK) were obtained using pM-NS5A/F5-R5 as a template with primers F2 and R2 and primers F3(NK) and R3, respectively. Nucleotide sequences of each primer were as follows: F1, 5Ј-CGCGGATCCGTTCCGGCTCGTGGCTAAGG-3Ј; F2, 5Ј-CGCGGATCCGTGGGGTGCGGTTGCACAGG-3Ј; F3, 5Ј-CGCGGATCCGTCCGGCGTGCAAACCTCTT-3Ј; F3(NK), 5Ј-CGCGGATCCGTCCGGCGTGCAGACCTCTC-3Ј; R1, 5Ј-CCCAAGCTTTTAGCAGCAGACGATGTCGTC-3Ј; R2, 5Ј-CCCAAGCTTTTAGTCAACGGCCGACGATCC-3Ј; and R3, 5Ј-CCCAAGCTTTTACCTCTTTCTCCGTGGAGG-3Ј.
Cell culture
Human osteosarcoma-derived Saos-2 cells and human hepatoblastoma-derived HepG2 cells were grown in Dulbecco's modified Eagle's medium supplemented with glutamine and 10% fetal bovine serum. For stimulation of apoptosis, transfected Saos-2 cells were incubated for the times shown in the figures with 10 ng/ml TNF-␣ (Sigma) and 50 g/ml CHX. The caspase inhibitor Z-VAD-fmk (Peptide Institute, Inc.) was added to cells at 50 M 1 h before treatment with TNF-␣. Poly(I-C) was added at 100 g/ml with 50 g/ml CHX for 8 h.
Transfection and protein detection
Cells were transfected with pCMV-derived plasmids using FuGENE 6 Transfection Reagent (Boehringer). Expression of proteins derived from plasmids in cells was examined by SDS-PAGE followed by Western blotting analysis as described previously . The antibodies used in this experiment were anti-NS5A antibody (Hijikata et al., 1993b) , anti-core antibody (515S, provided by Dr. Michinori Kohara, The Metropolitan Institute of Medical Science, Tokyo, Japan), anti-E-tag antibody (Promega), anti-Aequorea victoria GFP antibody (Molecular Probes), and anti-FLAG antibody (Sigma).
Immunofluorescence
Saos-2 cells were fixed with methanol:acetone (1:1). After fixation, cells were blocked in PBS containing 0.2% bovine serum albumin (Sigma) for 30 min and incubated with anti-NS5A antibody or anti-E-tag antibody for 45 min. After being washed with PBS, the cells were incubated with rhodamine-conjugated secondary antibody and 4Ј,6-diamidino-2-phenylindole (DAPI). After being washed, the samples were mounted on glass slides and observed by fluorescence microscopy.
Transcriptional activation assay
HepG2 and Saos-2 cells were used in this assay. The reporter gene plasmid, pFR-Luc (Stratagene), possessing five Gal4-DNA-binding sites following the luciferase gene, was cotransfected with each pM expression plasmid in the presence or in the absence of pFC-PKA plasmid, which expresses the ␣-catalytic subunit of PKA (Stratagene). The cells were harvested at 24 h after transfection, and luciferase activity was quantified using a commercial kit according to the manufacturer's protocol (Promega). The efficiency of transfection was monitored by cotransfection of pRL-TK plasmid, expressing Renilla luciferase (Promega). All assays were repeated three times, and the luciferase activity was expressed as the mean of relative values over that of pM.
